We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Please provide your email address to receive an email when new articles are posted on . In a head-to-head trial of the Amplatzer Amulet and Watchman FLX left atrial appendage closure devices, the ...
European regulators have approved an expanded indication for the Boston Scientific Corporation BSX WATCHMAN® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients with atrial ...
The global left atrial appendage closure (LAAC) devices market is projected to register a robust growth from 2025 to 2033.
Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...
In the showdown between left atrial appendage (LAA) closure devices, the Amplatzer Amulet outperformed Watchman for peridevice leaks (PDL) in one trial longer term but not in another. At 12 months of ...
On the basis of outcomes, there was no clear winner from a trial that directly compared two modern devices used in patients undergoing percutaneous left atrial appendage (LAA) closure. But the devices ...
Sophia Antipolis, France – 30 Aug 2021: The Amplatzer Amulet Left Atrial Appendage Occluder has shown superior left atrial appendage (LAA) closure and noninferior safety and effectiveness for stroke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results